Motor neuron disease can be viewed as an umbrella term describing a heterogeneous
group of conditions, all of which are relentlessly progressive and ultimately fatal. The …

The last 30 years have seen a major advance in the understanding of the clinical and
pathological heterogeneity of amyotrophic lateral sclerosis (ALS), and its overlap with …

The identification of clinically relevant biomarkers for neurological diseases poses unique
challenges. These include an historical lack of availability of relevant tissues from the site of …

Frontotemporal involvement has been extensively investigated in amyotrophic lateral
sclerosis (ALS) but remains relatively poorly characterized in other motor neuron disease …

The ideal biomarker needs to be easy to quantify and measure, reproducible, not subject to
wide variation in the general population and unaffected by co-morbid factors. For evaluation …

Biomarkers have become the focus of intense research in the field of amyotrophic lateral
sclerosis (ALS), with the hope that they might aid therapy development efforts …

The understanding of neurodegenerative diseases, traditionally considered to be well-
defined entities with distinguishable clinical phenotypes, has undergone a major shift over …

The diagnosis of neurodegenerative diseases within neurology and psychiatry are
hampered by the difficulty in getting biopsies and thereby validating the diagnosis by …

A major evolution from purely clinical diagnoses to biomarker supported clinical diagnosing
has been occurring over the past years in neurology. High-throughput methods, such as …

Advances in the neurosciences have placed the field in the position where it is poised to
significantly reduce the burden of nervous system disorders. However, drug discovery …